Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies

Tumor heterogeneity is a fundamental feature of malignant tumors and a major driver of treatment resistance, ultimately contributing to treatment resistance, therapeutic failure, disease recurrence, and poor outcome. Rather than being static, heterogeneity arises early during tumorigenesis and continues to evolve during progression, metastasis, and therapeutic selection. Advances in single-cell and spatial omics, integrative multi-omics profiling, liquid biopsy, and computational modeling have markedly improved the characterization of heterogeneity across genetic, epigenetic, transcriptomic, phenotypic, and microenvironmental dimensions. However, translating heterogeneity profiling into routine clinical decision-making remains challenging due to sampling bias, technical variability, data-integration complexity, and the need for prospectively validated, actionable metrics. In this review, we summarize the biological origins and major classifications of tumor heterogeneity, discuss current approaches for its detection and longitudinal monitoring, examine its implications for established and emerging therapies, and highlight precision-oncology strategies aimed at anticipating, tracking, and ultimately exploiting heterogeneity to achieve durable cancer control.